Participant Flow Module
The Participant Flow Module provides information about the flow of participants through each stage of the clinical trial. This includes pre-assignment details, recruitment information, and the types of units analyzed, helping researchers understand how participants move through the study.
Participant Flow Module path is as follows:
Study -> Results Section -> Participant Flow Module
Participant Flow Module
Ignite Creation Date:
2025-12-24 @ 11:20 PM
Ignite Modification Date:
2025-12-25 @ 9:03 PM
NCT ID:
NCT04665856
Pre Assignment Details:
A total of 123 participants were randomized in the study in a 1:1 ratio to receive tiragolumab plus atezolizumab and carboplatin + etoposide (CE) or placebo plus atezolizumab and CE. One participant from the tiragolumab arm did not receive tiragolumab and hence was included in the placebo arm group for safety analysis.
Recruitment Details:
Participants were enrolled at 17 investigative sites in China. This study is still ongoing.
Study:
NCT04665856
Study Brief:
Results Section:
NCT04665856